Study details
Enrolling now
COMT Inhibition in Alcohol Use Disorder/ADHD
University of Colorado, Denver
NCT IDNCT03904498ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
62
Study length
about 3.5 years
Ages
21–65
Locations
1 site in CO
About this study
This trial is testing whether tolcapone, a COMT inhibitor, helps with alcohol use, decision-making, brain activity related to alcohol cues, response inhibition, and attention. Participants will receive either tolcapone or a placebo for 1293 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo
- 2.Take Tolcapone
PhasePhase 2
DrugTolcapone
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low8%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
tolcapone
Drug routes
oral (Oral Tablet)
Body systems
Psychiatry / Mental Health